nals strains shows that intraceliular levels of ferredoxin are invariably reduced in the resistant strains relative to a sensitive strain. Similarly, Northern blot analysis shows that ferredoxin mRNA levels are reduced 50-65% in resistant strains. Using nuclear run-on assays, we show that ferredoxin gene crip tion is reduced 40-65% in resistant strains. Sequence comparison of the region 5' of the ferredoxin gene among drugsensitive and -resistant strains reveals two point mutations, at -178 and -239 nucleotides relative to the start of transcriWtion, in a resistant strain. Interestingly, a protein of 23 kDa binds to a 28-base-pair region that encompasses the mutation at -239 nucleotides. The binding affinity of this protein appears to be reduced in the mutant. These data strongly correlate drug resistance with altered regulation of ferdoxin gene transcription. A reduction in gene transcription results in decreased intracellular levels of ferredoxin. This, in turn, may play a role in metronidazole resistance by decreasing the ability of the cell to activate the drug.
Trichomonas vaginalis, a sexually transmitted, protozoan parasite, is a common and widespread cause of vaginitis. Trichomonads are ancient eukaryotes with a number of biochemical peculiarities (1, 2) . They are aerotolerant anaerobes that lack mitochondria and, instead, have an unusual organelle involved in carbohydrate catabolism-the hydrogenosome (3) . This organelle is the site of fermentative oxidation of pyruvate, coupled to ATP production via substrate-level phosphorylation.
Hydrogenosomes play an essential role in the drug susceptibility of T. vaginalis. Trichomoniasis is treated with metronidazole [1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole], a drug frequently used to treat infections caused by a number of anaerobic pathogens (e.g., Entamoeba, Giardia, Clostridium, and Bacteroides) (4) (5) (6) (7) . Metronidazole is administered in an inactive form and enters the cell through diffusion (8, 9) . In trichomonads, the drug is then activated to its cytotoxic form, within the hydrogenosome. Two hydrogenosomal proteins, pyruvate ferredoxin oxidoreductase and ferredoxin, play a critical role in the reductive activation of metronidazole ( Fig. 1) . Metronidazole is activated via the transfer ofa single electron from ferredoxin to the nitro group of the drug, resulting in the formation of a free radical. The antimicrobial effect of metronidazole is attributed to the reactivity and dismutation of this free radical (8, 10) .
Clinical isolates of T. vaginalis that exhibit lower susceptibility to metronidazole have been identified (11) (12) (13) . Measured under anaerobic conditions, the mean lethal concentrations (MLCs) of metronidazole for these isolates are e5-10 times that of drug-sensitive strains (13) . Biochemical studies on the ferredoxin-dependent reduction of nitroimidazole derivatives in one of these resistant strains (CDC085) have provided evidence that the reductive activation of metronidazole is diminished relative to a drug-sensitive strain (Cl). These observations led to the proposal that ferredoxin, the proximal reductant of the drug, may have either altered redox properties or reduced intracellular levels in resistant strain CDC085 (14, 15) .
We have tested the hypothesis that ferredoxin expression is altered in drug-resistant T. vaginalis by comparing the intracellular levels of the protein and its mRNA in four resistant strains, including CDC085, and a sensitive strain. The structure and transcriptional regulation of the ferredoxin gene have also been investigated. Our data are consistent with altered regulation of ferredoxin gene transcription playing a role in metronidazole resistance.
MATERIALS AND METHODS
Strains and Cultures. Strain designations, ATCC numbers, and MLCs of metronidazole, determined under anaerobic conditions, for T. vaginalis are as follows: strain C1, ATCC 30001 (MLC = 0.5 Ag/ml) (13) ; strain NYH286, ATCC 50148 (MLC = 1.6 pig/ml) (11) ; strain JH32A-4, ATCC 30238 (MLC, not determined) (12) ; strain RU382, ATCC 50141 (MLC = 6.3 pug/ml) (11) ; strain RU393, ATCC 50142 (MLC = 16 jig/ml) (11) ; and strain CDC085, ATCC 50143 (MLC = 16 ILg/ml) (11) . Strains were grown in Diamond's TYM as described (16) .
Immunoblot Analysis. Cells were pelleted and extracts were prepared as described (17) . Thirty micrograms of protein was fractionated by electrophoresis on a SDS/10% polyacrylamide gel and blotted onto nitrocellulose. The blot was allowed to react with an anti-ferredoxin antibody and antigen-antibody complexes were detected using 125I-labeled protein A as described (17) .
Northern Blot Analysis. Total RNA was isolated by a modified guanidinium thiocyanate procedure (18) . Ten micrograms of total RNA was separated on a 1.2% agarose/2.2 M formaldehyde gel and transferred to nitrocellulose. Filters were hybridized and washed as described (19) .
Amplifiation and Cloning of Genomic DNA. Genomic DNA was isolated as described (18) . PCRs were performed using 1 (19) . PCR products were ligated into the plasmid Bluescript and sequenced by the dideoxy method (Sequenase kit, United States Biochemical).
Nuclear Run-On Assays. Cells (109) were collected, washed in ice-cold phosphate-buffered saline, and lysed in 0.5% Nonidet P-40. Nuclei were pelleted and resuspended, and 32p was incorporated into nascent RNA as described (20) and modified by Johnson et Mobility Shift Assays. Cells were lysed and nuclei were isolated as described (20) . Nuclei were incubated in a hypertonic buffer followed by dialysis as described by Wu (22) (11) (12) (13) . Immunoblot analysis using polyclonal antiserum raised against T. vaginalis ferredoxin (17, 19) shows that the intracellular level of this protein is significantly reduced in all four resistant cell lines (Fig. 2) (Fig. 3 Left). Quantitation of mRNA levels using liquid scintillation spectroscopy (data not shown) revealed that ferredoxin mRNA is reduced -=50% in three of the resistant strains (RU382, RU393, and CDC085). One resistant strain (JH 32A-4) has a reduction in ferredoxin mRNA of =65%. T. vaginalis ferredoxin is found in hydrogenosomes (16, 29) , the site of metronidazole activation (Fig. 1) . Thus, to exclude the possibility that an alteration resulting in generalized reduction of mRNAs encoding hydrogenosomal proteins has occurred in resistant lines, we measured the level of an mRNA encoding a second hydrogenosomal protein. The RNA blot shown in Fig. 3 Left was stripped and rehybridized with a DNA probe encoding the hydrogenosomal protein ,B-succinyl CoA synthetase (C. J. Lahti and P.J.J., unpublished data). The signal for this mRNA is roughly equivalent or slightly higher in the resistant lines relative to sensitive ones (Fig. 3 Right). The levels of P-succinyl CoA synthetase detected in strains RU393 and CDC085 are slightly higher because of loading slightly more RNA in these lanes.
To determine if lower levels of ferredoxin mRNA result from a reduction in ferredoxin gene transcription, we measured nascent ferredoxin RNA using a nuclear run-on assay. An additional sensitive strain (NYH286) that was isolated in the clinic at approximately the same time as the resistant strains was included to exclude the possibility that changes in ferredoxin transcription are an artifact caused by prolonged culture of sensitive strain C1. We also monitored the transcription of T. vaginalis rRNA, tubulin, and 3-succinyl CoA synthetase genes as controls. The level of ferredoxin gene transcription in resistant lines was shown to be reduced 40-65% relative to sensitive lines (Table 1 and Fig. 4) . The degree to which transcription is reduced is similar to the reduction in steady-state mRNA. This strongly argues that altered regulation of ferredoxin gene transcription is responsible for reduced levels of the mRNA in resistant lines. Furthermore, the sequence of the ferredoxin mRNA (19) is identical in resistant strain CDC085 and sensitive stain C1 (data not shown), making it highly improbable that differential RNA degradation plays a role in regulating ferredoxin mRNA levels.
To search for alterations in transcriptional regulatory elements of the ferredoxin gene, we have compared the upstream sequences in four drug-resistant (JH 32A-4, RU382, RU393, and CDC085) and two drug-sensitive (Cl and NYH286) strains. DNA fragments of 757 nt were amplified from genomic DNA using PCR. These fragments, containing sequences -560 to +197 bp relative to the start offerredoxin gene transcription, were cloned and sequenced. The sequences ofthe sensitive strains and three resistant strains, JH 32A-4, RU393, and CDC085, are identical throughout the entire region. However, two mutations, at -178 bp and -239 bp relative to the start of transcription, were found in resistant strain RU382 (Fig. 5) . To ensure that these mutations are not errors introduced by Taq polymerase during PCR, we have sequenced eight clones derived from two independent PCR reactions using strain RU382 genomic Tub, a-tubulin; SCS, a-subunit of succinyl CoA synthetase; Fd, ferredoxin. Blots were hybridized with 32P-labeled, nascent transcripts generated in nuclei isolated from drug-sensitive strain C1 and drug-resistant strain RU382. Plasmid DNAs were used as negative controls (data not shown). Quantitation by liquid scintillation spectroscopy is listed in Table 1. DNA. All clones contain both mutations, which makes PCR errors highly unlikely.
We have investigated whether the mutation(s) upstream of the ferredoxin gene in strain RU382 might influence protein binding and, thus, reduce transcription. A fragment of 215 bp containing both mutations was 32P end-labeled, mixed with T. vaginalis nuclear extracts, and analyzed by PAGE. Migration of the fragment was slowed, indicating that a protein bound to the fragment (data not shown). To delineate the binding site, an exonuclease III protection assay (26) was performed using the 215-bp fragment. Fig. 6 A and B shows mapping of the boundary of the binding site on the coding and noncoding strands, respectively. When labeling the coding strand, protein(s) protecting -226 to -246 nt, relative to the start of transcription, is observed at lower exonuclease concentration (Fig. 6A, lane 2) . With increasing enzyme concentration, the boundary of the protected region is shown to be approximately -226 nt (lane 4) . Similarly, at a lower enzyme concentration, protein(s) protecting nucleotides -239 to -247 is found using the noncoding strand as template (Fig.  6B, lane 2) (Fig. 6 A and B, lanes 1 and 3) ; however, these do not interfere with our analysis. The size of these fragments indicates that the strong stops result from exonuclease III digesting the template from both 3' ends and stopping when the enzymes meet at the center of the template.
-239 Cl ATAATTr T T TGAAAAG& ACCGATCAA TATGACAGGT TAGAGAATTA RU382 ********** ******T*** ********** ********** ********** These exonuclease protection assays map the binding of a protein to an -28-bp region that encompasses the mutation at -239 nt found in drug-resistant strain RU382 (Fig. 6) . We have confirmed that a protein does bind to this sequence by using the 28-bp region in mobility shift assays. Two doublestranded 28-oligonucleotide fragments were generated (underlined in Fig. 5 ). One 28-nt oligomer (ds28) is identical to the sequence found in drug-sensitive strain C1. The other (dr28) contains the A -+ T transversion at -239 nt and is identical to the sequence found in drug-resistant strain RU382. The oligomers were cloned into the plasmid pBluescript and probes containing the 28-bp region of interest as well as 22 bp of pBluescript polylinker sequence were generated. Each probe (ds28 and dr28) was incubated with a nuclear extract made from drug-sensitive strain C1 in the presence ofpoly(dI-dC) as nonspecific DNA competitor (Fig.  7 ). ds28 and dr28 were shown to be bound by a protein(s) in the extract (lanes 1 and 9) . Sequence specificity of binding was demonstrated by the ability of an excess of the unlabeled probe to compete for binding (lanes 2-7 and 10-15).
We have examined whether this DNA binding protein has a greater affinity for ds28 than dr28, as predicted if the mutation in dr28 alters the binding of a protein involved in ferredoxin gene transcription. Such a decrease in affinity could, in principle, result in the 50% reduction of ferredoxin gene transcription observed in resistant strain RU382. In competition assays, using the unlabeled 28-nt oligomers at 25, 50, and 100 molar excess, ds28 is shown to compete significantly better than dr28 for protein binding (lanes 2-7 and 10-15). These data indicate that the mutation at -239 nt results in a decreased affinity for binding of the protein.
To exclude the possibility that a protein is specifically binding to the 22-nt pBluescript sequence contained in the probes, a random 28-nt sequence was cloned into the EcoRV site of pBluescript and released by digestion with HindIlI and Pst I. This fragment thus contains the same 22 nt of pBluescript and does not compete for binding with ds28 or dr28 probe (lanes 8 and 16) .
To further characterize this DNA binding protein, we have used UV light to crosslink the protein to a ds28 probe containing BrdUrd. SDS/PAGE analysis shows that a pro-FIG. 7. Mobility shift assays using oligonucleotides derived from drug-sensitive strain C1 (oligomer 28) and drug-resistant strain RU382 (oligomer dr28). Oligonucleotides were 32P end-labeled, incubated with nuclear extracts made from drug-sensitive strain C1, and size-fractionated on polyacrylamide gels. The oligomer derived from strain C1 (ds28) was used in lanes 1-8; the mutant oligomer (dr28) derived from strain RU382 was used in lanes [9] [10] [11] [12] [13] [14] [15] [16] tein with an apparent molecular mass of roughly 23 kDa is crosslinked to the DNA (Fig. 8) . Treatment ofthe crosslinked product with proteinase K abolishes the signal, as predicted if the probe is specifically bound by protein (lane 3).
DISCUSSION
We have compared strains of the protozoan parasite T. vaginalis that have differing susceptibilities to the drug metronidazole. In T. vaginalis, the antimicrobial effect of metronidazole results when the drug is reduced within the hydrogenosome, via the transfer of an electron from the hydrogenosomal protein ferredoxin to the nitro group of the drug (8) (9) (10) . This study shows that intracellular levels of ferredoxin and its mRNA are significantly reduced in four metronidazole-resistant strains of T. vaginalis. Recently, we have extended our analyses to include an additional three drug-resistant and two drug-sensitive lines. Consistent with the data shown here, there is significantly less ferredoxin and its mRNA in these drug-resistant lines. Thus, it is improbable that differences in ferredoxin levels merely reflect strain variation, as seven drug-resistant lines have reduced levels relative to three drug-sensitive lines. These data provide a strong correlation between decreased intracellular levels of ferredoxin and drug resistance. This is consistent with resistance resulting from a decreased ability of the cell to reduce metronidazole to its cytotoxic form.
Under anaerobic conditions, these drug-resistant strains exhibit a low level of metronidazole resistance (11, 13) . They are still capable of drug activation, although the efficiency of activation is significantly lower than in drug-sensitive cells (14, 15) . Thus it is reasonable that the 50-65% reduction in ferredoxin levels could lead to the resistant phenotype described, although this has yet to be directly demonstrated. It might be predicted that highly resistant T. vaginalis strains would abolish ferredoxin activity entirely. In this regard, it is interesting to note that Tritrichomonasfoetus strains that are highly resistant to metronidazole lack detectable enzymatic activities for pyruvate:ferredoxin oxidoreductase and hydrogenase, two other hydrogenosomal proteins that are involved in electron transport within the organelle (e.g., ref. 30 ). The molecular basis of these altered enzyme activities has not been reported. Hydrogenase activity would not appear to be essential for metronidazole activation in anaerobic protozoa, as Giardia and Entamoeba are highly susceptible to metronidazole and do not contain this enzyme. Hydrogenase does, however, appear to play a critical role in metronidazole activation in Clostridium (6) .
Reduced intracellular levels of ferredoxin and its mRNA are accompanied by a comparable decrease At present, we cannot rule out the possibility that the mutation at -239 nt is a nonfunctional polymorphism. In this regard, it is significant to note that the only other examined gene encoding a hydrogenosomal protein, the 3-succinyl CoA synthetase gene, has a sequence at -210 nt relative to the start of transcription that is identical at 17 of 20 nt to the sequence encompassing and surrounding nt -239 of the ferredoxin gene (unpublished data). This apparent sequence conservation provides further evidence that the sequence may be involved in transcription regulation. Also, it is noteworthy that analysis of the ferredoxin gene and flanking DNA shows that polymorphisms are rare (unpublished data). Definitive analysis ofthe biological role this DNA motifplays in gene transcription, as well as drug resistance, awaits the development of a transformation assay for T. vaginalis.
